A single center, retrospective study of efficacy and safety of secukinumab in moderate-to-severe plaque psoriasis patients in Greece
Latest Information Update: 08 Jun 2021
Price :
$35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 08 Jun 2021 Primary endpoint (Psoriasis Area and Severity Index (PASI) <-3 at week 4, 16, 52, 78, and clinical predictors of PASI <-3 and PASI100 responses at week 52 and 78) has been met.
- 08 Jun 2021 New trial record